3rd Quarter - Report

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$650,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

E-labeling; Issues related to the HR 7085, the BIOSECURE Act, and US manufacturing of pharmaceuticals; Issues related to PBM reform.

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
LISA LANGENDERFER New Legislative Director, Rep. Brad Wenstrup (OH-02); Policy Advisor; House Republican Conference; Senior Legislative Assistant, Rep. Jim Renacci (OH-16)
ART MOTTA —
CAROLINE QUAT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7085 (118th)

Taxation/Internal Revenue Code TAX

Issues related to COVID vaccine access and reimbursement; Issues related to the Orphan Drug Tax Credit; issues related to the deduction of research and development expenditures; H.R. 1350, Camerons Law; S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023.

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
LISA LANGENDERFER New Legislative Director, Rep. Brad Wenstrup (OH-02); Policy Advisor; House Republican Conference; Senior Legislative Assistant, Rep. Jim Renacci (OH-16)
ART MOTTA —
CAROLINE QUAT —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2673 (118th), H.R. 1350 (118th), S. 866 (118th)

Copyright/Patent/Trademark CPT

Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform; Issues related to pharmaceutical intellectual property (IP); General patent issues; Issues related to FDA Orange Book patent listings.

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
LISA LANGENDERFER New Legislative Director, Rep. Brad Wenstrup (OH-02); Policy Advisor; House Republican Conference; Senior Legislative Assistant, Rep. Jim Renacci (OH-16)
ART MOTTA —
CAROLINE QUAT —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Health Issues HCR

H.R. 5539/S.3131 ORPHAN Cures Act, amending orphan drug exclusion in IRA; Issues related to expanding orphan drug exclusion in IRA; Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language); FDA modernization policy issues; Issues related to FDA proposed regulation of lab developed tests; Reauthorization of the pediatric priority review voucher program; Reauthorization of newborn screening programs; Medicare drug price negotiation; Medicaid Drug Rebate Program proposed rule; Medicare Part D reform and inflation penalties; Issues related to drug pricing; Issues related to reform of pharmacy benefit managers; PBM Reform (misc. bills); General issues related to health equity in rare disease and clinical trials; General issues related to rare disease and orphan drugs; Issues related to the price and manufacture of inhaled medicines; Education to Hill staff on next generation propellant and PFAS; AZ sustainability platform; Issues related to importation of drugs; Issues related to march-in rights; Issues related to RSV monoclonal antibody manufacture and distribution; Issues related to COPD patient access through CMMI demonstration models; Rare Pediatric Disease Priority Review Voucher; H.R.7085 BioSecure Act.

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
LISA LANGENDERFER New Legislative Director, Rep. Brad Wenstrup (OH-02); Policy Advisor; House Republican Conference; Senior Legislative Assistant, Rep. Jim Renacci (OH-16)
ART MOTTA —
CAROLINE QUAT —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 3131 (118th), H.R. 7085 (118th), H.R. 5539 (118th)

Medicare/Medicaid MMM

Amending Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub L 117-169; Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No 117-169); e-labeling - allowing FDA to finalize a rule to allow digital versions of prescriptions; Value-based payment arrangements; CMMI; CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure; Efforts to improve coding, coverage, and access for rare disease therapies; Medicaid Drug Rebate Program proposed rule, specifically the stacking rule; Medicare patient access to rare disease therapies, Part B and Part D drugs; Centers for Medicare and Medicaid Innovation (CMMI) policy issues; Center for Medicare and Medicaid Innovation models; General issues related to diagnostic reimbursement; H.R. 5539/S. 3131 Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act; HR1503/S2916 Prescription Information Modernization Act; H.R. 3876 Access to Genetic Counselor Services Act of 2023; H.R. 2666 Medicaid VBPs for Patients Act.

LobbyistCovered position, as disclosed
SARAH CUDWORTH ARBES —
KATIE JONES —
LISA LANGENDERFER New Legislative Director, Rep. Brad Wenstrup (OH-02); Policy Advisor; House Republican Conference; Senior Legislative Assistant, Rep. Jim Renacci (OH-16)
ART MOTTA —
CAROLINE QUAT —

Contacted: SENATE; Food & Drug Administration (FDA); White House Office; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: S. 3131 (118th), H.R. 1503 (118th), H.R. 5539 (118th), H.R. 5376 (118th), H.R. 2666 (118th), H.R. 3876 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.